Tufts CSDD CRA-RBQM Transition Study
Tufts CSDD is conducting new research on trends in study monitoring and data collection.
The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting new research aimed at understanding how study monitoring and data collection practices are changing and evolving. This research will assess how sponsor companies are approaching implementation of more centralized and risk-based monitoring approaches, and how sponsor and CRO field-based monitors are adjusting and adapting. Links to participate in this study can be found below:
- Sponsor companies, please click here to participate: Sponsor Survey
- Clinical research associates (CRAs), please click here to participate: CRA Survey
For more information, please contact Hana Do (Hana.Do@tufts.edu).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
May 12th 2025In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound) delivered significantly greater and sustained weight loss than semaglutide (Wegovy) over 72 weeks in adults with obesity or overweight and comorbidities.
